» Articles » PMID: 29196214

The Lysosomal Enzyme Alpha-Galactosidase A is Deficient in Parkinson's Disease Brain in Association with the Pathologic Accumulation of Alpha-synuclein

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2017 Dec 3
PMID 29196214
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The aberrant accumulation of alpha-synuclein (α-syn) is believed to contribute to the onset and pathogenesis of Parkinson's disease (PD). The autophagy-lysosome pathway (ALP) is responsible for the high capacity clearance of α-syn. ALP dysfunction is documented in PD and pre-clinical evidence suggests that inhibiting the ALP promotes the pathological accumulation of α-syn. We previously identified the pathological accumulation of α-syn in the brains of mice deficient for the soluble lysosomal enzyme alpha-Galactosidase A (α-Gal A), a member of the glycosphingolipid metabolism pathway. In the present study, we quantified α-Gal A activity and levels of its glycosphingolipid metabolites in postmortem temporal cortex specimens from control individuals and in PD individuals staged with respect to α-syn containing Lewy body pathology. In late-state PD temporal cortex we observed significant decreases in α-Gal A activity and the 46kDa "active" species of α-Gal A as determined respectively by fluorometric activity assay and western blot analysis. These decreases in α-Gal A activity/levels correlated significantly with increased α-syn phosphorylated at serine 129 (p129S-α-syn) that was maximal in late-stage PD temporal cortex. Mass spectrometric analysis of 29 different isoforms of globotriaosylceramide (Gb), a substrate of α-Gal A indicated no significant differences with respect to different stages of PD temporal cortex. However, significant correlations were observed between increased levels of several Gb isoforms and with decreased α-Gal A activity and/or increased p129S-α-syn. Deacylated Gb (globotriaosylsphingosine or lyso-Gb) was also analyzed in PD brain tissue but was below the limit of detection of 20pmol/g. Analysis of other lysosomal enzymes revealed a significant decrease in activity for the lysosomal aspartic acid protease cathepsin D but not for glucocerebrosidase (GCase) or cathepsin B in late-stage PD temporal cortex. However, a significant correlation was observed between decreasing GCase activity and increasing p129S-α-syn. Together our findings indicate α-Gal A deficiency in late-stage PD brain that correlates significantly with the pathological accumulation of α-syn, and further suggest the potential for α-Gal A and its glycosphingolipid substrates as putative biomarkers for PD.

Citing Articles

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.

Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z Cell Mol Life Sci. 2024; 81(1):382.

PMID: 39223418 PMC: 11368888. DOI: 10.1007/s00018-024-05419-5.


Inherited Metabolic Disorders: From Bench to Bedside.

Fonseca T, Macedo M Biomedicines. 2024; 12(1).

PMID: 38255278 PMC: 10813142. DOI: 10.3390/biomedicines12010174.


The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and Cancer.

Stoka V, Vasiljeva O, Nakanishi H, Turk V Int J Mol Sci. 2023; 24(21).

PMID: 37958596 PMC: 10650516. DOI: 10.3390/ijms242115613.


Enzymatic properties and clinical associations of serum alpha-galactosidase A in Parkinson's disease.

Mizutani Y, Nawashiro K, Ohdake R, Tatebe H, Shima S, Ueda A Ann Clin Transl Neurol. 2023; 10(9):1662-1672.

PMID: 37496179 PMC: 10502655. DOI: 10.1002/acn3.51856.


Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models.

Drobny A, Boros F, Balta D, Huarcaya S, Caylioglu D, Qazi N Transl Neurodegener. 2023; 12(1):31.

PMID: 37312133 PMC: 10262594. DOI: 10.1186/s40035-023-00363-z.


References
1.
Chu Y, Dodiya H, Aebischer P, Olanow C, Kordower J . Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009; 35(3):385-98. DOI: 10.1016/j.nbd.2009.05.023. View

2.
Xu Y, Barnes S, Sun Y, Grabowski G . Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res. 2010; 51(7):1643-75. PMC: 2882741. DOI: 10.1194/jlr.R003996. View

3.
Borsini W, Giuliacci G, Torricelli F, Pelo E, Martinelli F, Scordo M . Anderson-Fabry disease with cerebrovascular complications in two Italian families. Neurol Sci. 2002; 23(2):49-53. DOI: 10.1007/s100720200025. View

4.
Gegg M, Burke D, Heales S, Cooper J, Hardy J, Wood N . Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012; 72(3):455-63. PMC: 3638323. DOI: 10.1002/ana.23614. View

5.
DeVeber G, Schwarting G, Kolodny E, Kowall N . Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992; 31(4):409-15. DOI: 10.1002/ana.410310410. View